Anastrozole during steroid cycle

Anastrozole has been tested for reducing estrogens, including estradiol, in men. [13] Excess estradiol in men can cause benign prostatic hyperplasia , gynecomastia , and symptoms of hypogonadism . It can also contribute to increased risk of stroke, heart attack, chronic inflammation, prostate enlargement and prostate cancer. [14] Some athletes and body builders use anastrozole as part of their steroid cycle to reduce and prevent symptoms of excess estrogen-- gynecomastia , emotional lability and water retention. [13] Study data suggest dosages of  mg to 1 mg a day reduce serum estradiol by approximately 50% in men, which differs in postmenopausal women. [15]

CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.

A multi-center, single-arm, open-label study was conducted in 28 girls with McCune-Albright Syndrome and progressive precocious puberty aged 2 to < 10 years. All patients received a 1 mg daily dose of ARIMIDEX. The trial duration was 12 months. Patients were enrolled on the basis of a diagnosis of typical (27/28) or atypical (1/27) McCune-Albright Syndrome, precocious puberty, history of vaginal bleeding, and/or advanced bone age. Patients' baseline characteristics included the following: a mean chronological age of ± years, a mean bone age of ± years, a mean growth rate of ± cm/year and a mean Tanner stage for breast of ± . Compared to pre-treatment data there were no on-treatment statistically significant reductions in the frequency of vaginal bleeding days, or in the rate of increase of bone age (defined as a ratio between the change in bone age over the change of chronological age). There were no clinically significant changes in Tanner staging , mean ovarian volume, mean uterine volume and mean predicted adult height. A small but statistically significant reduction of growth rate from ± cm/year to ± cm/year was observed but the absence of a control group precludes attribution of this effect to treatment or to other confounding factors such as variations in endogenous estrogen levels commonly seen in McCune-Albright Syndrome patients.

Anastrozole during steroid cycle

anastrozole during steroid cycle


anastrozole during steroid cycleanastrozole during steroid cycleanastrozole during steroid cycleanastrozole during steroid cycleanastrozole during steroid cycle